ArticleCureus2026
Severe Dengue-Associated Hepatitis in an Adolescent Treated With Oral Acetylcysteine: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue infection may lead to liver involvement ranging from mild transaminase elevation to severe hepatitis and, rarely, acute liver failure. Management is mainly supportive, and no specific therapy exists. We report the case of a 13-year-old adolescent with dengue with warning signs who developed severe hepatitis (aspartate aminotransferase (AST) 2034 U/L, alanine transaminase (ALT) 532 U/L) and thrombocytopenia. Oral N-acetylcysteine (NAC) was initiated as adjuvant therapy. During hospitalisation, a reduction in aminotransferase levels, clinical improvement, and recovery of platelet count were observed. These changes occurred during the course of illness; however, this temporal association does not establish causality and may reflect the expected recovery phase of dengue infection. This case describes the use of NAC as an adjuvant therapy in severe dengue-associated hepatitis. Further studies are required to evaluate its potential role in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.